Zoetis, Inc. (ZTS)
72.97
+0.11
(+0.15%)
USD |
NYSE |
Sep 11, 16:00
73.12
+0.15
(+0.21%)
After-Hours: 20:00
Zoetis Enterprise Value : 37.78B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 37.78B |
| September 10, 2026 | 37.74B |
| September 09, 2026 | 37.92B |
| September 08, 2026 | 38.03B |
| September 04, 2026 | 38.96B |
| September 03, 2026 | 39.16B |
| September 02, 2026 | 39.11B |
| September 01, 2026 | 39.56B |
| August 31, 2026 | 39.49B |
| August 28, 2026 | 39.59B |
| August 27, 2026 | 38.63B |
| August 26, 2026 | 39.67B |
| August 25, 2026 | 39.57B |
| August 24, 2026 | 39.52B |
| August 21, 2026 | 39.75B |
| August 20, 2026 | 38.63B |
| August 19, 2026 | 39.32B |
| August 18, 2026 | 38.19B |
| August 17, 2026 | 37.78B |
| August 14, 2026 | 38.12B |
| August 13, 2026 | 38.97B |
| August 12, 2026 | 38.02B |
| August 11, 2026 | 38.77B |
| August 10, 2026 | 38.55B |
| August 07, 2026 | 37.65B |
| Date | Value |
|---|---|
| August 06, 2026 | 39.56B |
| August 05, 2026 | 38.37B |
| August 04, 2026 | 39.05B |
| August 03, 2026 | 39.49B |
| July 31, 2026 | 39.57B |
| July 30, 2026 | 39.05B |
| July 29, 2026 | 39.84B |
| July 28, 2026 | 39.66B |
| July 27, 2026 | 39.42B |
| July 24, 2026 | 38.77B |
| July 23, 2026 | 38.45B |
| July 22, 2026 | 38.29B |
| July 21, 2026 | 38.77B |
| July 20, 2026 | 39.12B |
| July 17, 2026 | 39.27B |
| July 16, 2026 | 39.41B |
| July 15, 2026 | 38.43B |
| July 14, 2026 | 38.24B |
| July 13, 2026 | 38.79B |
| July 10, 2026 | 38.86B |
| July 09, 2026 | 38.66B |
| July 08, 2026 | 38.66B |
| July 07, 2026 | 39.16B |
| July 06, 2026 | 38.80B |
| July 02, 2026 | 38.54B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 209.77B |
| Elanco Animal Health, Inc. | 14.96B |
| Boston Scientific Corp. | 74.40B |
| Eli Lilly & Co. | 1.096T |
| Merck & Co., Inc. | 402.09B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 691.00M |
| Revenue (Quarterly) | 2.468B |
| Total Expenses (Quarterly) | 1.777B |
| EPS Diluted (Quarterly) | 1.654 |
| Gross Profit Margin (Quarterly) | 71.47% |
| Profit Margin (Quarterly) | 28.00% |
| Earnings Yield | 8.33% |
| Operating Earnings Yield | 11.41% |
| Normalized Earnings Yield | 8.610 |